iOnctura
PrivateLast Round
Series B
Jun 20, 2024
Est. Valuation
$139.6M
Total Funding Raised
$111.26M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
iOnctura is a biotechnology company focused on developing next-generation bio-molecules for the treatment of cancer and fibrosis through innovative therapeutics that target immunosuppression in the tumor microenvironment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iOnctura Comparables
Compare iOnctura with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rhizen Pharmaceuticals AG | 81% | |
| Secura Bio | 72% | |
| Anaveon | 71% |
iOnctura Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 20, 2024 | ||||
| Grant | Dec 20, 2022 | ||||
| Debt | Sep 28, 2022 | ||||
| Series A Extension | Jul 14, 2020 | ||||
| Series A | Jan 23, 2020 | ||||
Seed | Jun 20, 2017 |
Key People
Founding team and executive leadership
iOnctura Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant, Series B |
| XGEN Venture | Series B |
| Syncona | Series B |
| Fongit | Debt |
| 3B FUTURE Health Fund | Series B, Series A Extension |
| M Ventures | Series A, Series B |
| VI Partners | Series B, Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 969% MoM, from 29 to 310.
- Jan 9, 2026
CEO to present at the 2026 J.P. Morgan Healthcare Conference.
iOnctura Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about iOnctura's valuation, stock price, and market status.
Is iOnctura a public or private company?
iOnctura is a private company.
What is the current stock price of iOnctura?
iOnctura is a private company with no public stock price. No recent secondary market data is available.
How much is iOnctura worth (valuation)?
iOnctura's valuation is estimated at $139.6M based on funding round data.
Can I buy iOnctura stock?
iOnctura shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was iOnctura's last funding round?
iOnctura's most recent funding round was Series B on June 20, 2024.
Who are the main investors in iOnctura?
Key investors in iOnctura include Syncona, 3B FUTURE Health Fund, VI Partners, Inkef Capital, Syncona Limited.
Will iOnctura IPO soon?
No public IPO plans have been announced for iOnctura.
How can I track iOnctura secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor iOnctura's secondary market activity and sign up for updates.